Evidence map›Paper›PMID 40264031›Full record

ArticleBMC infectious diseases2025

Efficacy and safety of intrapleural administration of sodium bicarbonate in patients with acute empyema and complicated parapneumonic effusion: protocol for a prospective, single-arm, interventional study.

Yuichiro Suzukawa, Shuhei Teranishi, Sachi Takakura, Ryo Nakadegawa, Shunsuke Okazaki, Anna Tanaka, Shinya Matsushita, Tatsuya Muraoka, Tomofumi Hirose, Chihiro Maeda and 6 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Local management of pleural infection: a narrative review.European journal of medical research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yuichiro Suzukawa *Respiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Shuhei Teranishi *Respiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan. teranishi.shu.su@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0003-2365-144X
Sachi TakakuraRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Ryo NakadegawaRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Shunsuke OkazakiRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Anna TanakaRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Shinya MatsushitaRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Tatsuya MuraokaRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Tomofumi HiroseRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Chihiro MaedaRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Kenichi SekiRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Ken TashiroRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Nobuaki KobayashiDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3 - 9 Fukuura, Kanazawa-Ku, Yokohama, 236 - 0004, Japan.
Masaki YamamotoRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Makoto KudoRespiratory Disease Center, Yokohama City University Medical Center, 4 - 57 Urafune-Cho, Minami-Ku, Yokohama, 232 - 0024, Japan.
Takeshi KanekoDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3 - 9 Fukuura, Kanazawa-Ku, Yokohama, 236 - 0004, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe standard treatment for acute empyema/complicated parapneumonic effusion (CPPE) is antibiotic administration and continuous chest drainage. However, adequate drainage becomes impossible in multichambered pleural effusion and some patients may require surgery or may die. In Japan, intrapleural urokinase is frequently used to restore drainage effects; however, its supply was suspended in 2022 owing to difficulties in procuring the raw materials. In recent years, the effectiveness of intrapleural sodium bicarbonate administration for empyema/CPPE has been reported; however, complications such as hemothorax and pneumothorax occurred frequently because the research protocol involved repeated thoracentesis. Therefore, we designed an interventional study to investigate the efficacy and safety of intrapleural sodium bicarbonate administration combined with continuous chest drainage in patients with empyema/CPPE.

methodsThis study will include patients with empyema/CPPE who have been administered antibiotics and still have pleural effusion after > 12 h of continuous chest drainage. Sodium bicarbonate (50 mL) will be administered into the pleural cavity through the double-lumen catheter of the chest tube once daily for a maximum of 3 days. The primary endpoint will be treatment success rate, defined as the rate of avoiding surgery or death within 30 days of sodium bicarbonate administration. The 95% confidence interval for the treatment success rate will be calculated using the Clopper-Pearson method. DISCUSSION: Sodium bicarbonate can be chemically synthesized; therefore, there is little concern about supply shortages and it is inexpensive. Therefore, if it is effective against empyema/CPPE, it would prove beneficial for Japan and other countries. Once this study shows the efficacy and safety of intrapleural sodium bicarbonate administration for empyema/CPPE, we plan to conduct a prospective randomized controlled trial using a placebo.

trial registrationThis study was approved by the Yokohama City University Clinical Research Review Committee (ethics approval number: CRB24-001) on May 8, 2024, and registered with the Japan Clinical Trials Registry (jRCTs031240093) on May 17, 2024. Written informed consent will be obtained from the participants or their proxies.

Indexed as

EmpyemaEmpyema, PleuralPleural EffusionSodium BicarbonateAdultAgedAnti-Bacterial AgentsDrainageFemaleHumansJapanMaleMiddle AgedProspective StudiesTreatment OutcomeAnti-Bacterial AgentsSodium BicarbonateChest drainageComplicated parapneumonic effusionEmpyemaSodium bicarbonateUrokinase

Identifiers

PMID40264031
PMCPMC12016439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.